Clinical trialsCompany release

Citius Oncology presents exploratory quality-of-life data for Lymphir in relapsed or refractory CTCL

🇺🇸 Citius Pharmaceuticals, Inc. (CTXR) · Wed 04 Nov 2026

Patient-reported results from pivotal Study 302 suggest responders had sustained quality-of-life gains, though the analyses were descriptive and fall outside the FDA-approved prescribing information.

Citius Oncology announced on 4 November 2026 exploratory patient-reported quality-of-life findings from Study 302, the pivotal trial of Lymphir (denileukin diftitox-cxdl) in relapsed or refractory cutaneous T-cell lymphoma (CTCL). The data were given in an oral presentation at the EORTC-CLTG meeting in Berlin, held on 8-10 October.

According to the company, patients who responded to treatment showed sustained improvement in both skin-related and overall quality of life, compared with non-responders. Among heavily pretreated patients who had itch at baseline, 32% achieved a clinically meaningful reduction in itch.

Citius Oncology stressed the limits of the work. The analyses were descriptive, Study 302 was not powered to assess these outcomes, and the findings do not appear in the FDA-approved prescribing information for Lymphir.

Exploratory, non-powered endpoints of this kind are generally regarded as hypothesis-generating rather than confirmatory, and they cannot normally support labelling claims on their own.

What it means for your team

  • The quality-of-life and itch findings are exploratory and not part of the US label, so they should not be treated as approved product claims.
  • Medical and promotional review teams should ensure any reference to these data is clearly framed as descriptive and non-labelled.
  • Market-access teams may find patient-reported outcomes useful as supporting context in discussions, but the lack of statistical powering limits their weight.
  • Confirmatory evidence would be needed before these outcomes could inform formal labelling or value assessments.

Company's press release (SEC filing): Citius Pharmaceuticals, Inc. ↗

Article written by VigiEye from the official source (Citius Pharmaceuticals, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →